obicetrapib 10 mg + ezetimibe 10 mg FDC daily

DRUG2 trials

Sponsors

NewAmsterdam Pharma

Conditions

Coronary Artery DiseaseLipidemiaMetabolic Syndrome (MetS)Plaque, AtheroscleroticType 2 Diabetes (T2DM)

Phase 3

A CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary Plaque

Active, not recruitingNCT06305559

NewAmsterdam PharmaCoronary Artery Disease, Lipidemia, Plaque, Atherosclerotic

Start: 2024-05-16End: 2028-02-01Target: 300Updated: 2026-04-09

A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome

Active, not recruitingNCT07219602

NewAmsterdam PharmaLipidemia, Metabolic Syndrome (MetS), Type 2 Diabetes (T2DM)

Start: 2025-12-11End: 2028-06-01Target: 300Updated: 2026-09-09

Related Papers

Rationale and design of the REMBRANDT trial: A phase 3 study to evaluate the effect of obicetrapib/ezetimibe on coronary plaque characteristics

American Heart Journal2025-07-173 citations